O'Byrne Jason 4

What Happened
Jason O'Byrne, Chief Financial Officer of Vir Biotechnology (VIR), sold 1,634 shares on 2026-02-24 at $9.53 per share, generating proceeds of $15,576. This was a sale (not a purchase) and was executed under an automatic arrangement to cover tax withholding obligations related to restricted stock units.

Key Details

• Transaction date: 2026-02-24; Filing date: 2026-02-26 (filing not marked late)
• Price: $9.53 per share; Total proceeds: $15,576
• Shares owned after transaction: Not reported in this Form 4
• Footnote: The sale was automatic and mandatory under a Rule 10b5-1 arrangement to satisfy the issuer's tax withholding for RSU vesting (not a discretionary trade by the reporting person)

Context
Automatic sales to cover taxes on vested RSUs are routine and do not necessarily signal the insider’s view of the company; purchases are generally more informative about confidence. This transaction was a withholding-related sale under a pre-established plan rather than a voluntary market-timed sell.